Skip to content
Operation Infinite Justice – Lifestyle
Author:
VERAXA Biotech GmbH
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
July 29, 2026
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
July 24, 2026
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
July 23, 2026
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
July 20, 2026
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
July 13, 2026
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
July 10, 2026
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
July 6, 2026
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
July 2, 2026
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
June 24, 2026
1
2
Next Page
→